RWE and real-world data are being increasingly utilized to support rare disease trial designs and regulatory decisions in contexts of limited patient numbers. https://www.einpresswire.com/article/834691992/orphan-drugs-market-to-reach-usd-486-51-billion-by-2032-on-rare-disease-focus-datam-intelligence